GC
SCMP

Guggenheim Capital’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Guggenheim Capital’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-80,930
Closed -$954K – 2894
2017
Q3 		$954K Buy
80,930
+5,148
+7% +$57.7K ﹤0.01% 2113
2017
Q2 		$795K Sell
75,782
-7,097
-9% -$72.3K ﹤0.01% 2195
2017
Q1 		$911K Buy
+82,879
New +$962K ﹤0.01% 2142
2014
Q4 		– Sell
-10,238
Closed -$67K – 3161
2014
Q3 		$67K Sell
10,238
-3,539
-26% -$23.5K ﹤0.01% 2910
2014
Q2 		$95K Sell
13,777
-3,971
-22% -$28.1K ﹤0.01% 3016
2014
Q1 		$127K Sell
17,748
-1,121
-6% -$9.59K ﹤0.01% 2987
2013
Q4 		$177K Buy
+18,869
New +$135K ﹤0.01% 2874

Other funds holding SCMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Guggenheim Capital's SCMP Position: Q4 2017 in Review

Guggenheim Capital sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q4 2017, closing a stake of 80,930 shares — an estimated $954K sold.

Guggenheim Capital first reported a position in SCMP in Q4 2013 and held it in 7 quarters. The position peaked at $954K in Q3 2017. 188 funds tracked by Wall St. Rank hold SCMP as of Q4 2017.

  • Guggenheim Capital reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Guggenheim Capital sold 80,930 Sucampo Pharmaceuticals, Inc. shares in Q4 2017, an estimated $954K.
  • Guggenheim Capital first reported a position in Sucampo Pharmaceuticals, Inc. in Q4 2013 and held it in 7 quarters.
  • Guggenheim Capital's Sucampo Pharmaceuticals, Inc. position peaked at $954K in Q3 2017.
  • 188 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q4 2017.

Based on Guggenheim Capital's 13F filing for Q4 2017, filed 14 Feb 2018.